UMC Health System Partners with Omnicell for Advanced Services Solutions to Streamline Medication Management & Enhance Clinical Outcomes

Omnicell | February 15, 2022

Omnicell, Inc., a leading provider of medication management and adherence tools for health systems and pharmacies, today announced that UMC Health System (“UMC”) in Lubbock, Texas, has selected Omnicell’s comprehensive portfolio of Advanced Services solutions to support key pharmacy initiatives, including acute care, outpatient, retail, and 340B program strategies.

UMC has signed a 10-year sole source agreement for Omnicell’s cloud-based portfolio of solutions, including central pharmacy automation and point of care dispensing systems. The partnership is also expected to support UMC’s goals of expanding community pharmacy services through opportunities with Omnicell’s 340B services and EnlivenHealth’s patient engagement solutions, helping UMC to drive operational efficiency across its continuum of care. More importantly, these solutions will empower pharmacy staff and clinicians to focus on higher value tasks that support patient safety.

As a public hospital with a 40-year tenure supporting the Lubbock community, UMC has experienced an increase in demand for its services. According to U.S. Census data, Texas has one of the highest uninsured population rates – at 18.4 percent in 2019, nearly double the national average. Programs like the federal 340B Drug Pricing Program and technology-enabled patient engagement solutions are intended to help improve health outcomes for these underserved communities.

“At UMC, our top priority is patient safety and ensuring healthy outcomes for our community. Partnering with Omnicell, we are building an advanced pharmacy technology strategy that aligns with our vision to streamline and advance the pharmacy and nursing practice across our system. Most importantly, we are laying a technology foundation that will enable the best patient care.”

John Lowe, vice president of Support Services at UMC Health System

UMC has embraced the industry-defined vision of the Autonomous Pharmacy, a roadmap designed to develop a zero-error, fully automated medication management infrastructure. Through automation, intelligence, and expert services, the Autonomous Pharmacy is expected to drive performance and outcomes, and empower clinicians to shift their focus from manual administrative functions to patient support needs.

“As medication management becomes more complex, we believe health systems need end-to-end, cloud-based solutions that will allow them to work smarter, while supporting safe, efficient pharmacy care,” said Scott Seidelmann, executive vice president and chief commercial officer at Omnicell. “We’re confident that Omnicell’s partnership with UMC will provide comprehensive solutions that bridge acute and ambulatory care to help enhance performance and that are designed to deliver the highest levels of patient safety across the health system.”

About UMC

UMC Health System is a national award-winning health system comprised of over 4,600 team members and more than 30 care locations. We are proud to partner with Texas Tech University Health Sciences Center to provide the best care to West Texas and Eastern New Mexico. Whether you are managing a chronic condition, dealing with an unexpected illness, or simply working to stay healthy, we are passionate about getting you well and helping you stay that way. At UMC, Our Passion is You.

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Healthcare facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. Institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. 


Are you looking for a reliable medical provider? Look no further! We are excited to introduce our new online tool that simplifies the process of finding a trusted healthcare professional.


Are you looking for a reliable medical provider? Look no further! We are excited to introduce our new online tool that simplifies the process of finding a trusted healthcare professional.

Related News


Global Health Technology Platform Provider Proximie Commences Rollout of PxLens Using Vuzix M4000™ Smart Glasses

Prnewswire | April 06, 2023

Vuzix® Corporation a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, announced that Proximie, a global health technology platform provider, has commenced rollout of PxLens following its initial introduction earlier this year. PxLens, Proximie's smart glasses solution for use in operating rooms, uses Vuzix M4000™ smart glasses. PxLens offers quick setup and use when paired with the Proximie mobile app and seamless integration into Proximie's cloud-based platform for telepresence, content management, and insights from the operating room. Vuzix M4000 smart glasses offer the performance and versatility of Vuzix M400 smart glasses combined with see-through waveguide technology. They are the first enterprise-focused smart glasses using revolutionary Vuzix waveguides and offer a see-through heads-up display. Voice activated commands enable hands-free control, and the M4000's robust battery packs can be swapped mid-procedure to ensure that even the longest procedures can be fully streamed and recorded. Comfortable head mounting enables surgeons to share a first-person perspective of open surgeries and minimally invasive procedures, allowing participants observing remotely to view high-definition pictures and streamed videos of these surgeries and procedures, providing them opportunities to advise where necessary and/or learn from cutting-edge surgical techniques. Within the Proximie platform these procedures are recorded and saved in a secure library to be reviewed, edited, analyzed and shared. Pilot procedures with surgeons wearing the PxLens were conducted in the United Kingdom and the United States by Proximie in 2022. Procedures included colorectal, otolaryngology, orthopedic, plastics, and urology surgeries and user feedback has been uniformly positive. "Vuzix smart glasses represent a lightweight, wearable, hands-free solution that delivers high performance on every measure," said Dr. Nadine Hachach-Haram, founder and CEO of Proximie. "The PxLens is another step on Proximie's journey to help surgeons deliver effective and efficient care. It provides an insightful first-person perspective and helps make the recording and sharing of procedures ubiquitous. This improves patient care, training, skills development, and overall surgical efficiency." "Proximie's selection and exclusive use of Vuzix smart glasses for such a key element of their telepresence platform represents another significant win for us in the healthcare space," said Paul Travers, President and CEO of Vuzix. "Our see-through M4000 smart glasses represent one of the most optimal solutions for use in operating rooms, whether for remote support, training, information management or actual surgeries, and we look forward to working with Proximie to support their global rollout of PxLens across their customer base." About Proximie Founded in 2016, Proximie's healthcare platform brings together telepresence, content management, and data insights to help hospitals, surgeons, and medical device companies improve patient outcomes and drive productivity. With Proximie, expertise can be shared from anywhere using any device, and data from procedures can be securely captured, managed, and analyzed at scale. Proximie operates in more than 50 countries, serving over 500 healthcare providers and 16,000 users.

Read More


Gaylord Specialty Healthcare First in Nation to Adopt Ground-Breaking Pharyngeal Electrical Stimulation Technology to Treat Patients with Dysphagia

Prnewswire | May 10, 2023

Gaylord Specialty Healthcare, a nonprofit rehabilitation-focused healthcare system, is proud to announce that it is the first healthcare organization in the nation to use the Phagenyx® Neurostimulation System from Phagenesis, Ltd. to treat dysphagia among stroke patients. Dysphagia – or the difficulty or inability to swallow – affects millions worldwide and is a common diagnosis among adult patients at long-term acute care hospitals, including Gaylord Hospital. Dysphagia following stroke is most often caused by damage to the parts of the brain that control and coordinate swallowing and can lead to serious medical complications, including aspiration pneumonia. The device uses first-of-its-kind Pharyngeal Electrical Stimulation (PES) technology to precisely target and stimulate sensory nerves within the pharyngeal mucosa critical for safe and efficient swallowing function. Clinical studies have shown PES using the FDA-approved Phagenyx device can improve swallowing function, reduce aspiration risk, and improve patient outcomes. The device has received regulatory approval in multiple countries and is used in leading hospitals and rehabilitation centers worldwide. "Gaylord prides itself on being an early adopter of technologies that can make a difference in our patients' functional recovery," stated Peter Grevelding, PT, MSPT, Gaylord Specialty Healthcare Vice President of Clinical Operations and Executive Director, Milne Institute for Healthcare Innovation. "Based on the results of several clinical trials, the Phagenyx System has shown to be safe and reliable," Grevelding continued. "We have seen great results with the very first patients. It will be a valuable tool in improving the quality of care for our stroke patients who face swallowing problems." "We are pleased to partner with Gaylord Specialty Healthcare and provide their patients with access to our Phagenyx device," said Reinhard Krickl, CEO of Phagenesis, Ltd. "Our mission is to transform the lives of individuals with dysphagia by providing them with a revolutionary treatment that significantly improves their ability to swallow and eat." About Gaylord Specialty Healthcare Gaylord Specialty Healthcare is a rehabilitation-focused, nonprofit health system headquartered in Wallingford, Connecticut, that provides inpatient and outpatient care for people at every point in their journey from illness or injury to maximum recovery. Gaylord Specialty Healthcare is anchored by Gaylord Hospital, a long-term acute care hospital, and includes Gaylord Outpatient Services and Gaylord Physical Therapy for patients who require diagnosis and treatment on an outpatient basis. Gaylord's Milne Institute for Healthcare Innovation is a hub for accelerating world-class rehabilitative research, technology development and innovation to improve the quality of life and function of people around the world. Together, these entities deliver a complete continuum of rehabilitative care driven by clinical experience, innovation and human compassion.

Read More


Komodo Health Introduces MapEnhance To Accelerate Multidimensional Insights for Healthcare and Life Sciences

Businesswire | April 27, 2023

Komodo Health today unveils MapEnhance, a network of specialty data partners that seamlessly connects into Komodo’s technology platform. MapEnhance extends the insight-generating capacity of Komodo’s Healthcare Map by combining it with exclusive and highly informative data curated from Komodo’s partners. Available only through the Komodo platform, MapEnhance provides Komodo’s customers with access to a multidimensional, real-world view of clinical events and patient populations at a level of resolution not previously available. MapEnhance enables customers to migrate away from legacy data aggregators and marketplaces and take advantage of a more cost-effective, technologically-enabled approach that drives rich, rapid insights. Users can more quickly perform comprehensive analytics, develop higher-performing predictive models, and conduct healthcare research on a unique combination of data products that support the unique needs of Life Sciences and healthcare teams spanning Clinical Development, Commercialization, Medical Affairs, and more. On top of Komodo's Healthcare Map – the industry’s most comprehensive, accurate source of de-identified patient-level data insights and analytics available – MapEnhance adds even more depth, dimension, and visibility into clinical encounters and patient populations. "Access to higher-fidelity patient journeys is required for real-world research at scale, and Komodo is leading the way for the industry by increasing connectivity between specialized datasets and the Healthcare Map,” said Arif Nathoo, MD, CEO and Co-Founder, Komodo Health. “As the FDA continues to advance standards for real-world evidence, Komodo is helping customers understand bias and reduce the inaccuracies perpetuated by legacy aggregators and marketplaces, which lack accountability for data quality and fidelity. MapEnhance introduces a superior alternative to what’s currently available on the market." MapEnhance curates insights from specialized proprietary partners, including Invitae, PointClickCare, Trio Health, and more. Users can rapidly identify a patient cohort in Komodo’s Healthcare Map and then see how much additional visibility MapEnhance partners can unlock on that cohort. Because MapEnhance is delivered on Komodo’s unified platform, data is cleansed, standardized, and seamlessly integrated, offering faster and timelier insights through a centralized process and technology infrastructure. MapEnhance combines insights generated from Komodo’s Healthcare Map with Precision Molecular Diagnostics: Features a range of proprietary cytogenetics, flow cytometry, FISH, and targeted or broad-panel genetics tests run on tissue, germ-line, and liquid biopsies (ctDNA) and focused on multiple therapeutic areas including cancer, cardiology, neurology, pediatric genetics, metabolic disorders, immunology, hematology, and more. High-Volume Standard Laboratory Diagnostics: Derived from the largest clinical laboratory providers in the U.S., including a broad menu of commonly ordered inpatient and outpatient lab tests, to drive earlier visibility into diagnosis and disease progression in both common and rare diseases. Electronic Medical Records: Unlocks unparalleled visibility into clinical encounters, with observations captured at the point of care, including characteristics of patients with highly complex conditions such as autoimmune diseases, diabetes, Alzheimer’s, and other acute and chronic conditions. Inpatient and Outpatient Facility Chargemasters: Provides deeper visibility into individual components of cost and utilization (including device-specific detail) associated with episodes of care across hospital settings, such as emergency departments, intensive-care units, and ambulatory surgery centers. “Our partnership with Komodo on MapEnhance presents an exciting opportunity to merge Trio’s unique real-world ecosystems, including direct access to healthcare providers, their clinical EMR data, and physician notes, with other powerful data sources,” said Brent Clough, CEO of Trio Health. “We are thrilled that MapEnhance will make it possible to append our data and insights with those from genetic testing, lab testing, claims, and hospitalizations. This is a huge step forward to bring together comprehensive clinical and cost-of-care insights to deliver real-world treatment recommendations that wouldn’t be possible without Komodo’s platform and expertise.” “PointClickCare’s clinical and comprehensive data shines an important light on insights into the long-term care of older adults — a population at higher risk for severe illness, and one that is often overlooked,” said Tara Goodman, Vice President, Life Sciences at PointClickCare. “Our partnership with Komodo and the introduction of MapEnhance are helping to break down silos in healthcare data across the industry and empower healthcare stakeholders with the most complete high-definition view of real-world patient journeys to fuel new research and enhance our collective understanding across complex disease areas.” Komodo Health is an industry leader in healthcare technology and data connectivity, powering secure, compliant use of de-identified patient data with analytics and insights that is unified within the Komodo platform. The continued enhancement of Komodo’s Healthcare Map, which powers the company’s technology platform and cloud-based application suite, is helping equip customers with reliable insights on disease trends to inform business decisions and ultimately help close gaps in care. About Komodo Health Komodo Health is a technology platform company creating the new standard for real-world data and analytics by pairing the industry’s most complete view of patient encounters with enterprise software and machine learning that connects the dots between individual patient journeys and large-scale health outcomes. Across Life Sciences, payers, providers, and developers, Komodo helps its customers unearth patient-centric insights at scale — marrying clinical data with advanced algorithms and AI-powered software solutions to inform decision-making, close gaps in care, address disease burden, and help the enterprise create a more cost-effective, value-driven healthcare system.

Read More